Compounds > 1,2-bis(5-amidino-2-benzimidazolyl)ethane
Page last updated: 2024-09-04

1,2-bis(5-amidino-2-benzimidazolyl)ethane and piritrexim

1,2-bis(5-amidino-2-benzimidazolyl)ethane has been researched along with piritrexim in 1 studies

Compound Research Comparison

Studies
(1,2-bis(5-amidino-2-benzimidazolyl)ethane)		Trials
(1,2-bis(5-amidino-2-benzimidazolyl)ethane)		Recent Studies (post-2010)
(1,2-bis(5-amidino-2-benzimidazolyl)ethane)		Studies
(piritrexim)		Trials
(piritrexim)		Recent Studies (post-2010) (piritrexim)
600124216

Protein Interaction Comparison

ProteinTaxonomy1,2-bis(5-amidino-2-benzimidazolyl)ethane (IC50)piritrexim (IC50)
Dihydrofolate reductase Mycobacterium avium0.0006
Dihydrofolate reductaseHomo sapiens (human)0.0024
Dihydrofolate reductaseLacticaseibacillus casei0.0015
Dihydrofolate reductaseSaccharomyces cerevisiae S288C0.031
Dihydrofolate reductaseEscherichia coli K-120.0244
Dipeptidyl peptidase 4Rattus norvegicus (Norway rat)0.011
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)0.038
Dihydrofolate reductasePneumocystis carinii0.0257
Aromatic-L-amino-acid decarboxylaseHomo sapiens (human)0.0006
Dihydrofolate reductaseCandida albicans0.04
Dipeptidyl peptidase 4Homo sapiens (human)0.014
5-hydroxytryptamine receptor 2BRattus norvegicus (Norway rat)0.0091
Mu-type opioid receptorCavia porcellus (domestic guinea pig)0.0043
Bifunctional dihydrofolate reductase-thymidylate synthaseToxoplasma gondii0.0134
Dihydrofolate reductaseRattus norvegicus (Norway rat)0.0031
Dihydrofolate reductase Pneumocystis jirovecii0.041

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Queener, SF1

Reviews

1 review(s) available for 1,2-bis(5-amidino-2-benzimidazolyl)ethane and piritrexim

ArticleYear
New drug developments for opportunistic infections in immunosuppressed patients: Pneumocystis carinii.
    Journal of medicinal chemistry, 1995, Nov-24, Volume: 38, Issue:24

    Topics: Animals; Drug Design; Humans; Immunosuppression Therapy; Molecular Structure; Opportunistic Infections; Pneumonia, Pneumocystis; Structure-Activity Relationship

1995